Interagency Coordinating Committee on the Validation of Alternative Methods Communities of Practice Webinar on New Approach Methodologies To Assess (Developmental) Neurotoxicity; Notice of Public Webinar; Registration Information, 72609-72610 [2021-27692]
Download as PDF
Federal Register / Vol. 86, No. 243 / Wednesday, December 22, 2021 / Notices
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: December 16, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–27691 Filed 12–21–21; 8:45 am]
BILLING CODE 4140–01–P
National Institute of Environmental
Health Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Interagency Coordinating Committee
on the Validation of Alternative
Methods Communities of Practice
Webinar on New Approach
Methodologies To Assess
(Developmental) Neurotoxicity; Notice
of Public Webinar; Registration
Information
National Institutes of Health
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Mechanism for TimeSensitive Research Opportunities in
Environmental Health Sciences (R21).
Date: January 10, 2022.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Laura A. Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, National Institute of Environmental
Health Sciences, Research Triangle Park, NC
27709, 984–287–3328, laura.thomas@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
17:55 Dec 21, 2021
[FR Doc. 2021–27690 Filed 12–21–21; 8:45 am]
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
Dated: December 16, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
Jkt 256001
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM)
announces a public webinar ‘‘New
Approach Methodologies to Assess
(Developmental) Neurotoxicity.’’ The
webinar is organized on behalf of
ICCVAM by the National Toxicology
Program Interagency Center for the
Evaluation of Alternative Toxicological
Methods (NICEATM). Interested persons
may participate via the web meeting
platform. Time will be allotted for
questions from the audience.
Information about the webinar and
registration are available at https://
ntp.niehs.nih.gov/go/commprac-2022.
DATES:
Webinar: January 25, 2022, 10:00 a.m.
to approximately 11:30 a.m. EST.
Registration for Webinar: January 4,
2022, until 11:30 a.m. EST January 25,
2022.
Registration to view the webinar is
required.
ADDRESSES: Webinar web page: https://
ntp.niehs.nih.gov/go/commprac-2022.
FOR FURTHER INFORMATION CONTACT: Dr.
Nicole Kleinstreuer, Acting Director,
NICEATM, email: nicole.kleinstreuer@
nih.gov, telephone: (984) 287–3150.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM promotes the
development and validation of toxicity
testing methods that protect human
health and the environment while
replacing, reducing, or refining animal
use. ICCVAM also provides guidance to
test method developers and facilitates
collaborations that promote the
development of new test methods. To
address these goals, ICCVAM will hold
a Communities of Practice webinar on
SUMMARY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
72609
‘‘New Approach Methodologies to
Assess (Developmental) Neurotoxicity.’’
The nervous system has unique
characteristics and can have different
sensitivity to toxic substances compared
to other organ systems. Effects of
chemicals on the nervous system can be
affected by concurrent exposures to
other substances. During early life
stages, exposure to neuroactive drugs
and environmental toxins can interact
and/or interfere with developmental
processes of the brain, which can in
turn result in structural and/or
functional alterations. Traditional
(developmental) neurotoxicity tests use
mammals, but the high cost and low
throughput of these tests make them
impractical to use for all chemicals of
potential concern. In addition, it is
challenging to correlate the
interpretation of animal data to complex
human neurological effects. Therefore,
interest is increasing in exploring
human cell-based assays, computational
systems, and other alternatives to
traditional animal tests that can be used
to predict chemical effects on the
developing and adult nervous system.
‘‘New approach methodologies’’
(NAMs) refers to any non-animal
technology or approach, or combination
of these, that can be used to provide
information on chemical hazard and
risk assessment. This webinar will
discuss NAMs that are being considered
or developed for assessing potential
effects of chemicals on the nervous
system. Key insights and ongoing
activities will be described in two
presentations featuring speakers from
U.S. federal research and regulatory
agencies. The preliminary agenda and
additional information about
presentations will be posted at https://
ntp.niehs.nih.gov/go/commprac-2022 as
available.
Webinar and Registration: This
webinar is open to the public with time
scheduled for questions by participants
following each presentation.
Registration for the webinar is required
and will be open from January 4, 2022,
through 11:30 a.m. EST on January 25,
2022. Registration is available at https://
ntp.niehs.nih.gov/go/commprac-2022.
Interested individuals are encouraged to
visit this web page to stay abreast of the
most current webinar information.
Registrants will receive instructions on
how to access and participate in the
webinar in the email confirming their
registration.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 17 federal
regulatory and research agencies that
require, use, generate, or disseminate
E:\FR\FM\22DEN1.SGM
22DEN1
72610
Federal Register / Vol. 86, No. 243 / Wednesday, December 22, 2021 / Notices
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability. ICCVAM also
promotes the scientific validation and
regulatory acceptance of testing
methods that more accurately assess the
safety and hazards of chemicals and
products and replace, reduce, or refine
animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of the National Institute of
Environmental Health Sciences and
provides the authority for ICCVAM
involvement in activities relevant to the
development of alternative test
methods. Additional information about
ICCVAM can be found at https://
ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM,
provides support for ICCVAM-related
activities, and conducts and publishes
analyses and evaluations of data from
new, revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative test methods
and strategies for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
Dated: December 16, 2021.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
Jkt 256001
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; National Center for
Advancing Translational Sciences Special
Emphasis Panel.
Date: February 23, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim,
Ph.D., Scientific Review Administrator,
Office of Grants Management and Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (301) 827–7940,
carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Name of Committee: National Advisory
Neurological Disorders and Stroke Council.
Date: February 2–3, 2022.
Open: February 2, 2022, 1:00 p.m. to 6:00
p.m.
Agenda: Report by the Director, NINDS;
Report by the Director, Division of
Extramural Activities; and Administrative
and Program Developments.
Open session will be videocast from this
link: https://videocast.nih.gov/.
Closed: February 3, 2022, 1:00 p.m. to 5:30
p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Rockville, MD 20852 (Virtual Meeting).
Contact Person: Robert Finkelstein, Ph.D.,
Director of Extramural Research, National
Institute of Neurological Disorders and
Stroke, NIH, 6001 Executive Blvd., Suite
3309, MSC 9531, Rockville, MD 20852, (301)
496–9248, finkelsr@ninds.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice at least 10 days in advance of the
meeting. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.ninds.nih.gov, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 16, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–27689 Filed 12–21–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Neurological
Disorders and Stroke Notice of
Meeting
BILLING CODE 4140–01–P
17:55 Dec 21, 2021
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
[FR Doc. 2021–27692 Filed 12–21–21; 8:45 am]
VerDate Sep<11>2014
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Neurological Disorders and Stroke
Council.
The meeting will be open to the
public. Individuals who plan to
participate and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Dated: December 16, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–27724 Filed 12–21–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Automated Commercial Environment
(ACE) Export Manifest for Air Cargo
Test: Extension of Test
U.S. Customs and Border
Protection; Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This notice announces that
U.S. Customs and Border Protection
SUMMARY:
E:\FR\FM\22DEN1.SGM
22DEN1
Agencies
[Federal Register Volume 86, Number 243 (Wednesday, December 22, 2021)]
[Notices]
[Pages 72609-72610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27692]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee on the Validation of
Alternative Methods Communities of Practice Webinar on New Approach
Methodologies To Assess (Developmental) Neurotoxicity; Notice of Public
Webinar; Registration Information
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) announces a public webinar ``New Approach
Methodologies to Assess (Developmental) Neurotoxicity.'' The webinar is
organized on behalf of ICCVAM by the National Toxicology Program
Interagency Center for the Evaluation of Alternative Toxicological
Methods (NICEATM). Interested persons may participate via the web
meeting platform. Time will be allotted for questions from the
audience. Information about the webinar and registration are available
at https://ntp.niehs.nih.gov/go/commprac-2022.
DATES:
Webinar: January 25, 2022, 10:00 a.m. to approximately 11:30 a.m.
EST.
Registration for Webinar: January 4, 2022, until 11:30 a.m. EST
January 25, 2022.
Registration to view the webinar is required.
ADDRESSES: Webinar web page: https://ntp.niehs.nih.gov/go/commprac-2022.
FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Acting
Director, NICEATM, email: [email protected], telephone: (984)
287-3150.
SUPPLEMENTARY INFORMATION:
Background: ICCVAM promotes the development and validation of
toxicity testing methods that protect human health and the environment
while replacing, reducing, or refining animal use. ICCVAM also provides
guidance to test method developers and facilitates collaborations that
promote the development of new test methods. To address these goals,
ICCVAM will hold a Communities of Practice webinar on ``New Approach
Methodologies to Assess (Developmental) Neurotoxicity.''
The nervous system has unique characteristics and can have
different sensitivity to toxic substances compared to other organ
systems. Effects of chemicals on the nervous system can be affected by
concurrent exposures to other substances. During early life stages,
exposure to neuroactive drugs and environmental toxins can interact
and/or interfere with developmental processes of the brain, which can
in turn result in structural and/or functional alterations. Traditional
(developmental) neurotoxicity tests use mammals, but the high cost and
low throughput of these tests make them impractical to use for all
chemicals of potential concern. In addition, it is challenging to
correlate the interpretation of animal data to complex human
neurological effects. Therefore, interest is increasing in exploring
human cell-based assays, computational systems, and other alternatives
to traditional animal tests that can be used to predict chemical
effects on the developing and adult nervous system.
``New approach methodologies'' (NAMs) refers to any non-animal
technology or approach, or combination of these, that can be used to
provide information on chemical hazard and risk assessment. This
webinar will discuss NAMs that are being considered or developed for
assessing potential effects of chemicals on the nervous system. Key
insights and ongoing activities will be described in two presentations
featuring speakers from U.S. federal research and regulatory agencies.
The preliminary agenda and additional information about presentations
will be posted at https://ntp.niehs.nih.gov/go/commprac-2022 as
available.
Webinar and Registration: This webinar is open to the public with
time scheduled for questions by participants following each
presentation. Registration for the webinar is required and will be open
from January 4, 2022, through 11:30 a.m. EST on January 25, 2022.
Registration is available at https://ntp.niehs.nih.gov/go/commprac-2022. Interested individuals are encouraged to visit this web page to
stay abreast of the most current webinar information. Registrants will
receive instructions on how to access and participate in the webinar in
the email confirming their registration.
Background Information on ICCVAM and NICEATM: ICCVAM is an
interagency committee composed of representatives from 17 federal
regulatory and research agencies that require, use, generate, or
disseminate
[[Page 72610]]
toxicological and safety testing information. ICCVAM conducts technical
evaluations of new, revised, and alternative safety testing methods and
integrated testing strategies with regulatory applicability. ICCVAM
also promotes the scientific validation and regulatory acceptance of
testing methods that more accurately assess the safety and hazards of
chemicals and products and replace, reduce, or refine animal use.
The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l-3) establishes
ICCVAM as a permanent interagency committee of the National Institute
of Environmental Health Sciences and provides the authority for ICCVAM
involvement in activities relevant to the development of alternative
test methods. Additional information about ICCVAM can be found at
https://ntp.niehs.nih.gov/go/iccvam.
NICEATM administers ICCVAM, provides support for ICCVAM-related
activities, and conducts and publishes analyses and evaluations of data
from new, revised, and alternative testing approaches. NICEATM and
ICCVAM work collaboratively to evaluate new and improved testing
approaches applicable to the needs of U.S. federal agencies. NICEATM
and ICCVAM welcome the public nomination of new, revised, and
alternative test methods and strategies for validation studies and
technical evaluations. Additional information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/niceatm.
Dated: December 16, 2021.
Brian R. Berridge,
Associate Director, National Toxicology Program.
[FR Doc. 2021-27692 Filed 12-21-21; 8:45 am]
BILLING CODE 4140-01-P